ELSEVIER

Clinica Chimica Acta 247 (1996) 201–202

Author index

Volume 247 (1996)

Agmon, V., R. Khosravi, S. Marchesini, T. Dinur, A. Dagan, S. Gatt, R. Navon, Intracellular degradation of sulforhodamine-G_{M1}: use for a fluorescence-based characterization of G_{M2}-gangliosidosis variants in fibroblasts and white blood cells **247**, 105
Akatuka, N., see Teramoto, T. **247**, 159
Albin, N., see Coward, L. **247**, 121
Asins, E., see Bolufer, P. **247**, 89

Bairati, C., see Lombardo, A. **247**, 39
Barnes, S., see Coward, L. **247**, 121
Biasioli, S., see Schiavon, R. **247**, 71
Bollini, D., see Lombardo, A. **247**, 39
Bolte, G., A. Osman, T. Mothes, M. Stern, Peptic-tryptic digests of gliadin: contaminating trypsin but not pepsin interferes with gastrointestinal protein binding characteristics **247**, 59
Bolufer, P., M.D. Torregrosa, L. Gomez, B. Munarriz, J.A. López, E. Asins, S. Espinoza, F. Vera, C. Vazquez, V. Guillem, Specific oncological contribution of cathepsin D and pS2 in human breast cancer: their relationship with TNM status, estradiol receptors, epidermal growth factor receptor and *neu* amplification **247**, 89
Bonnefont-Rousselot, D., see Lopez, O. **247**, 181
Burlina, A., see Lombardo, A. **247**, 39

Cavalcanti, G., see Schiavon, R. **247**, 71
Chang, Y.-J., see Terada, Y. **247**, 81
Chigorno, V., see Pitto, M. **247**, 143
Coward, L., M. Kirk, N. Albin, S. Barnes, Analysis of plasma isoflavones by reversed-phase HPLC-multiple reaction ion monitoring-mass spectrometry **247**, 121

Dagan, A., see Agmon, V. **247**, 105
De Fanti, E., see Schiavon, R. **247**, 71
Delattre, J., see Lopez, O. **247**, 181
Dinur, T., see Agmon, V. **247**, 105

Eberle, A.M., see Zilkens, T.M. **247**, 23
Eguchi, Y., see Terada, Y. **247**, 81
Emerit, J., see Lopez, O. **247**, 181
Espinoza, S., see Bolufer, P. **247**, 89

Furihata, K., see Tozuka, M. **247**, 175

Gatt, S., see Agmon, V. **247**, 105
Gentilini, M., see Lopez, O. **247**, 181
Giavarina, D., see Schiavon, R. **247**, 71
Gleason, J., see Prence, E.M. **247**, 167
Goi, G., see Lombardo, A. **247**, 39
Gomez, L., see Bolufer, P. **247**, 89
Guidi, G., see Schiavon, R. **247**, 71
Guillem, V., see Bolufer, P. **247**, 89

Hidaka, H., see Tozuka, M. **247**, 175
Hobbs, L., M. Mitra, R. Phillips, D. Smith, The activity of a blood type B specific exoglycosidase from *Glycine max* **247**, 7

Igbokwe, G.E., see Ilouno, L.E. **247**, 1
Ilouno, L.E., E.N. Shu, G.E. Igbokwe, An improved technique for the assay of red blood cell superoxide dismutase (SOD) activity **247**, 1

Kaneko, K., see Teramoto, T. **247**, 159
Katsuyama, T., see Tozuka, M. **247**, 175
Kawamura, M., see Teramoto, T. **247**, 159
Khosravi, R., see Agmon, V. **247**, 105
Kinoshita, M., see Teramoto, T. **247**, 159
Kirk, M., see Coward, L. **247**, 121
Kuhara, T., see Ning, C. **247**, 197

0009-8981/96/$15.00 © 1996 Elsevier Science B.V. All rights reserved

Liang, Y.-Q., see Teramoto, T. **247**, 159
Lombardo, A., C. Bairati, G. Goi, C. Roggi, L. Maccarini, D. Bollini, A. Burlina, Plasma lysosomal glycohydrolases in a general population **247**, 39
López, J.A., see Bolufer, P. **247**, 89
Lopez, O., D. Bonnefont-Rousselot, M. Mollereau, R. Olivier, L. Montagnier, J. Emerit, M. Gentilini, J. Delattre, Increased plasma thiobarbituric acid-reactive substances (TBARS) before opportunistic infection symptoms in HIV infected individuals **247**, 181

Maccarini, L., see Lombardo, A. **247**, 39
Marchesini, S., see Agmon, V. **247**, 105
Mathew, T.H., see Phillipov, G. **247**, 51
Matsumoto, I., see Ning, C. **247**, 197
Mitra, M., see Hobbs, L. **247**, 7
Mollereau, M., see Lopez, O. **247**, 181
Montagnier, L., see Lopez, O. **247**, 181
Mori, M., see Nagai, T. **247**, 189
Mothes, T., see Bolte, G. **247**, 59
Munarriz, B., see Bolufer, P. **247**, 89

Nagai, T., T. Tomizawa, K. Sudou, C. Shiozawa, M. Mori, Specific carbohydrate antigen LeY expression on lymphocytes in diabetes mellitus **247**, 189
Natowicz, M.R., see Prence, E.M. **247**, 167
Navon, R., see Agmon, V. **247**, 105
Ninan, V.T., see Phillipov, G. **247**, 51
Ning, C., T. Kuhara, I. Matsumoto, Simultaneous metabolic profile studies of three patients with fatal infantile mitochondrial myopathy-de Toni-Fanconi-Debré syndrome by GC/MS **247**, 197

Ohta, H., see Tozuka, M. **247**, 175
Okumura, N., see Tozuka, M. **247**, 175
Olivier, R., see Lopez, O. **247**, 181
Osman, A., see Bolte, G. **247**, 59
Ozawa, K., see Terada, Y. **247**, 81

Phillipov, G., V.T. Ninan, T.H. Mathew, Plasma 1,5-anhydro-D-glucitol concentration and its relation to other plasma components in renal failure and renal transplant recipients **247**, 51
Phillips, R., see Hobbs, L. **247**, 7
Pitto, M., V. Chigorno, M. Renlund, G. Tettamanti, Impairment of ganglioside metabolism in cultured fibroblasts from Salla patients **247**, 143
Prence, E.M., J. Gleason, M.R. Natowicz, Characterization of clinical assays for leukocyte and fibroblast alpha-*N*-acetylgalactosaminidase activities for the diagnosis of alpha-*N*-acetylgalactosaminidase deficiency **247**, 167

Renlund, M., see Pitto, M. **247**, 143
Roggi, C., see Lombardo, A. **247**, 39

Sakumoto, H., see Terada, Y. **247**, 81
Schiavon, R., E. De Fanti, D. Giavarina, S. Biasioli, G. Cavalcanti, G. Guidi, Serum paraoxonase activity is decreased in uremic patients **247**, 71
Schmidt-Gayk, H., see Zilkens, T.M. **247**, 23
Shimazu, N., see Teramoto, T. **247**, 159
Shiozawa, C., see Nagai, T. **247**, 189
Shu, E.N., see Ilouno, L.E. **247**, 1
Smith, D., see Hobbs, L. **247**, 7
Stern, M., see Bolte, G. **247**, 59
Sudou, K., see Nagai, T. **247**, 189
Suga, S., see Teramoto, T. **247**, 159

Tabata, R., see Terada, Y. **247**, 81
Takehiro, O., see Terada, Y. **247**, 81
Terada, Y., Y. Eguchi, Y.-J. Chang, R. Tabata, H. Sakumoto, O. Takehiro, S. Uno, K. Ozawa, Ketone body ratios of the superior and inferior vena cava and of pulmonary arterial blood compared to that of arterial blood: central venous ketone body ratio as a substitute for the arterial ketone body ratio **247**, 81
Teramoto, T., M. Kinoshita, M. Kawamura, Y.-Q. Liang, K. Kaneko, N. Shimazu, S. Suga, N. Akatuka, M. Yamanaka, Characterization of low-density-lipoprotein in apolipoprotein E deficiency in a patient without coronary atherosclerosis **247**, 159
Tettamanti, G., see Pitto, M. **247**, 143
Tomizawa, T., see Nagai, T. **247**, 189
Torregrosa, M.D., see Bolufer, P. **247**, 89
Tozuka, M., H. Ohta, H. Hidaka, N. Okumura, K. Furihata, T. Katsuyama, Influence of apolipoprotein E phenotypes on total serum cholesterol in Japanese children **247**, 175

Uno, S., see Terada, Y. **247**, 81

Vazquez, C., see Bolufer, P. **247**, 89
Vera, F., see Bolufer, P. **247**, 89

Yamanaka, M., see Teramoto, T. **247**, 159

Zilkens, T.M., A.M. Eberle, H. Schmidt-Gayk, Immunoluminometric assay (ILMA) for intact human proinsulin and its conversion intermediates **247**, 23

ELSEVIER

Clinica Chimica Acta 247 (1996) 203–205

Subject index

Volume (1996)

β-*N*-Acetyl hexosaminidase A; Lipid storage diseases; G_{M2} gangliosidosis; Tay-Sachs disease; G_{M2} ganglioside; Fluorescent G_{M1} ganglioside **247**, 105

Acridinium ester; Insulinoma; Diagnosis; Immunoassay; Luminescence **247**, 23

Alpha-*N*-acetylgalactosaminidase; Lysosomal storage disease; Schindler disease **247**, 167

1,5-Anhydro-D-glucitol; Renal failure; Renal transplant; Urate; Creatinine **247**, 51

Apolipoprotein E; Phenotypes; Serum cholesterol **247**, 175

Apoliprotein E deficiency; Coronary atherosclerosis; Small-dense LDL; Oxidative modified LDL; Type III hyperlipidemia **247**, 159

Arterial ketone body ratio (AKBR); Ketone body ratio; Central venous blood **247**, 81

Blood type; *Glycine max*; *Coffea canephora*; ELISA **247**, 7

BM-1; LeY antigen expression; CD subset; CD8; CD19 **247**, 189

Breast cancer; Cathepsin D; pS2; TNM status; Estradiol receptors; Epidermal growth factor receptor; *Neu* amplification **247**, 89

Brush border membranes; Coeliac disease; Gliadin peptic-tryptic digests; Frazer's fraction III **247**, 59

Cathepsin D; Breast cancer; pS2; TNM status; Estradiol receptors; Epidermal growth factor receptor; *Neu* amplification **247**, 89

CD subset; LeY antigen expression; BM-1; CD8; CD19 **247**, 189

CD19; LeY antigen expression; BM-1; CD subset; CD8 **247**, 189

CD8; LeY antigen expression; BM-1; CD subset; CD19 **247**, 189

Central venous blood; Arterial ketone body ratio (AKBR); Ketone body ratio **247**, 81

Coeliac disease; Brush border membranes; Gliadin peptic-tryptic digests; Frazer's fraction III **247**, 59

Coffea canephora; *Glycine max*; ELISA; Blood type **247**, 7

Coronary atherosclerosis; Apoliprotein E deficiency; Small-dense LDL; Oxidative modified LDL; Type III hyperlipidemia **247**, 159

Creatinine; 1,5-Anhydro-D-glucitol; Renal failure; Renal transplant; Urate **247**, 51

Cultured fibroblasts; Salla disease; Ganglioside metabolism; Sialic acid **247**, 143

Daidzein; Isoflavonoids; Dihydrodaidzein; *O*-Desmethylangolensin; Genistein **247**, 121

***O*-Desmethylangolensin**; Isoflavonoids; Daidzein; Dihydrodaidzein; Genistein **247**, 121

0009-8981/96/$15.00 © 1996 Elsevier Science B.V. All rights reserved

Diagnosis; Insulinoma; Immunoassay; Luminescence; Acridinium ester **247**, 23

Dihydrodaidzein; Isoflavonoids; Daidzein; *O*-Desmethylangolensin; Genistein **247**, 121

ELISA; *Glycine max*; *Coffea canephora*; Blood type **247**, 7

Epidermal growth factor receptor; Cathepsin D; Breast cancer; pS2; TNM status; Estradiol receptors; *Neu* amplification **247**, 89

Estradiol receptors; Cathepsin D; Breast cancer; pS2; TNM status; Epidermal growth factor receptor; *Neu* amplification **247**, 89

Fluorescent G_{M1} ganglioside; Lipid storage diseases; G_{M2} gangliosidosis; Tay-Sachs disease; *β-N*-acetyl hexosaminidase A; G_{M2} ganglioside **247**, 105

Frazer's fraction III; Brush border membranes; Coeliac disease; Gliadin peptic-tryptic digests **247**, 59

G_{M2} ganglioside; Lipid storage diseases; G_{M2} gangliosidosis; Tay-Sachs disease; *β-N*-acetyl hexosaminidase A; Fluorescent G_{M1} ganglioside **247**, 105

G_{M2} gangliosidosis; Lipid storage diseases; Tay-Sachs disease; *β-N*-acetyl hexosaminidase A; G_{M2} ganglioside; Fluorescent G_{M1} ganglioside **247**, 105

Ganglioside metabolism; Salla disease; Sialic acid; Cultured fibroblasts **247**, 143

General population; Plasma; Lysosomal glycohydrolases **247**, 39

Genistein; Isoflavonoids; Daidzein; Dihydrodaidzein; *O*-Desmethylangolensin **247**, 121

Gliadin peptic-tryptic digests; Brush border membranes; Coeliac disease; Frazer's fraction III **247**, 59

Glycine max; *Coffea canephora*; ELISA; Blood type **247**, 7

Haemodialysis; Paraoxonase; Uremic patients; Lipoproteins; High density lipoproteins **247**, 71

High density lipoproteins; Paraoxonase; Uremic patients; Haemodialysis; Lipoproteins **247**, 71

Human immunodeficiency virus; Thiobarbituric acid-reactive substances; Oxidative stress; Opportunistic infection **247**, 181

Immunoassay; Insulinoma; Diagnosis; Luminescence; Acridinium ester **247**, 23

Insulinoma; Diagnosis; Immunoassay; Luminescence; Acridinium ester **247**, 23

Isoflavonoids; Daidzein; Dihydrodaidzein; *O*-Desmethylangolensin; Genistein **247**, 121

Ketone body ratio; Arterial ketone body ratio (AKBR); Central venous blood **247**, 81

LeY antigen expression; BM-1; CD subset; CD8; CD19 **247**, 189

Lipid storage diseases; G_{M2} gangliosidosis; Tay-Sachs disease; *β-N*-acetyl hexosaminidase A; G_{M2} ganglioside; Fluorescent G_{M1} ganglioside **247**, 105

Lipoproteins; Paraoxonase; Uremic patients; Haemodialysis; High density lipoproteins **247**, 71

Luminescence; Insulinoma; Diagnosis; Immunoassay; Acridinium ester **247**, 23

Lysosomal glycohydrolases; Plasma; General population **247**, 39

Lysosomal storage disease; Alpha-*N*-acetylgalactosaminidase; Schindler disease **247**, 167

***Neu* amplification**; Cathepsin D; Breast cancer; pS2; TNM status; Estradiol receptors; Epidermal growth factor receptor **247**, 89

Nitroblue tetrazolium; Superoxide dismutase; Pre-eclamptic toxaemia; Pregnancy; Red blood cells **247**, 1

Opportunistic infection; Thiobarbituric acid-reactive substances; Oxidative stress; Human immunodeficiency virus **247**, 181

Oxidative modified LDL; Apoliprotein E deficiency; Coronary atherosclerosis; Small-dense LDL; Type III hyperlipidemia **247**, 159

Oxidative stress; Thiobarbituric acid-reactive substances; Human immunodeficiency virus; Opportunistic infection **247**, 181

Paraoxonase; Uremic patients; Haemodialysis; Lipoproteins; High density lipoproteins **247**, 71

Phenotypes; Apolipoprotein E; Serum cholesterol **247**, 175

Plasma; Lysosomal glycohydrolases; General population **247**, 39

Pre-eclamptic toxaemia; Superoxide dismutase; Pregnancy; Nitroblue tetrazolium; Red blood cells **247**, 1

Pregnancy; Superoxide dismutase; Pre-eclamptic toxaemia; Nitroblue tetrazolium; Red blood cells **247**, 1

pS2; Cathepsin D; Breast cancer; TNM status; Estradiol receptors; Epidermal growth factor receptor; *Neu* amplification **247**, 89

Red blood cells; Superoxide dismutase; Pre-eclamptic toxaemia; Pregnancy; Nitroblue tetrazolium **247**, 1

Renal failure; 1,5-Anhydro-D-glucitol; Renal transplant; Urate; Creatinine **247**, 51

Renal transplant; 1,5-Anhydro-D-glucitol; Renal failure; Urate; Creatinine **247**, 51

Salla disease; Ganglioside metabolism; Sialic acid; Cultured fibroblasts **247**, 143

Schindler disease; Alpha-*N*-acetylgalactosaminidase; Lysosomal storage disease **247**, 167

Serum cholesterol; Apolipoprotein E; Phenotypes **247**, 175

Sialic acid; Salla disease; Ganglioside metabolism; Cultured fibroblasts **247**, 143

Small-dense LDL; Apoliprotein E deficiency; Coronary atherosclerosis; Oxidative modified LDL; Type III hyperlipidemia **247**, 159

Superoxide dismutase; Pre-eclamptic toxaemia; Pregnancy; Nitroblue tetrazolium; Red blood cells **247**, 1

Tay-Sachs disease; Lipid storage diseases; G_{M2} gangliosidosis; β-*N*-acetyl hexosaminidase A; G_{M2} ganglioside; Fluorescent G_{M1} ganglioside **247**, 105

Thiobarbituric acid-reactive substances; Oxidative stress; Human immunodeficiency virus; Opportunistic infection **247**, 181

TNM status; Cathepsin D; Breast cancer; pS2; Estradiol receptors; Epidermal growth factor receptor; *Neu* amplification **247**, 89

Type III hyperlipidemia; Apoliprotein E deficiency; Coronary atherosclerosis; Small-dense LDL; Oxidative modified LDL **247**, 159

Urate; 1,5-Anhydro-D-glucitol; Renal failure; Renal transplant; Creatinine **247**, 51

Uremic patients; Paraoxonase; Haemodialysis; Lipoproteins; High density lipoproteins **247**, 71